Porfirias agudas: manifestaciones inespecíficas y manejo terapéutico específico
Revisión clínica, científica, teórica y documental teniendo como objetivo principal realizar una revisión sobre la porfiria aguda, su enfoque, diagnóstico y tratamiento. Se utilizó una metodología descriptiva, cualitativa y teórica que permitió la revisión bibliográfica de los estudios relacionados con la porfiria aguda, trastorno congénito poco frecuente que causa alteraciones en las enzimas de la biosíntesis del grupo hem. La importancia de esta patología radica en que se confunde con otras enfermedades debido al cuadro clínico complejo difícil de identificar, lo que ocasiona un diagnóstico tardío que puede comprometer la vida del paciente y por ello se conoce como enfermedad silenciosa. Como conclusión se recomienda mayor atención a los... Ver más
Guardado en:
0121-7372
2462-991X
29
2020-03-16
Revista Repertorio de Medicina y Cirugía - 2020
info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
| id |
15fcac37c4a5c9fa4940e512d0a621a4 |
|---|---|
| record_format |
ojs |
| institution |
FUNDACIÓN UNIVERSITARIA DE CIENCIA DE LA SALUD |
| thumbnail |
https://nuevo.metarevistas.org/FUNDACIONUNIVERSITARIADECIENCIADELASALUD/logo.png |
| country_str |
Colombia |
| collection |
Revista Repertorio de Medicina y Cirugía |
| title |
Porfirias agudas: manifestaciones inespecíficas y manejo terapéutico específico |
| spellingShingle |
Porfirias agudas: manifestaciones inespecíficas y manejo terapéutico específico Mejía, José Julián Jaramillo Trujillo, Gilberto Gómez, Luis Fernando Jaramillo, María Andrea Caballero Tovar, Dayana Milena diagnóstico Porfiria aguda clasificación tratamiento treatment classification Acute porphyria diagnosis |
| title_short |
Porfirias agudas: manifestaciones inespecíficas y manejo terapéutico específico |
| title_full |
Porfirias agudas: manifestaciones inespecíficas y manejo terapéutico específico |
| title_fullStr |
Porfirias agudas: manifestaciones inespecíficas y manejo terapéutico específico |
| title_full_unstemmed |
Porfirias agudas: manifestaciones inespecíficas y manejo terapéutico específico |
| title_sort |
porfirias agudas: manifestaciones inespecíficas y manejo terapéutico específico |
| title_eng |
Acute porphyrias: unspecific manifestations and specific therapeutic management |
| description |
Revisión clínica, científica, teórica y documental teniendo como objetivo principal realizar una revisión sobre la porfiria aguda, su enfoque, diagnóstico y tratamiento. Se utilizó una metodología descriptiva, cualitativa y teórica que permitió la revisión bibliográfica de los estudios relacionados con la porfiria aguda, trastorno congénito poco frecuente que causa alteraciones en las enzimas de la biosíntesis del grupo hem. La importancia de esta patología radica en que se confunde con otras enfermedades debido al cuadro clínico complejo difícil de identificar, lo que ocasiona un diagnóstico tardío que puede comprometer la vida del paciente y por ello se conoce como enfermedad silenciosa. Como conclusión se recomienda mayor atención a los factores precipitantes de los ataques agudos por la elevada morbimortalidad, así como hacer un diagnóstico rápido y oportuno por medios cualitativos y cuantitativos solicitando PBG (porfobilinógeno) y ALA (ácido delta aminolevulínico).
|
| description_eng |
This was a clinical, scientific, theoretical and documental review aimed to conduct a revision on the approach, diagnosis and treatment of acute porphyria. A descriptive, quantitative and theoretical methodology was used, allowing a bibliographic review of the studies on acute porphyria, an unusual congenital disorder characterized by the deficiency of specific enzymes involved in the heme group biosynthesis. This disease importance lies on being confused with other conditions due to its complex clinical manifestations leading to a delayed diagnosis which may become life-threatening thus it is known as a silent disease In conclusion, identifying the precipitating factors of acute attacks for its high morbidity and mortality, as well as achieving a rapid and timely diagnosis by using a quantitative or qualitative determination of PBG (porphobilinogen)) and ALA (delta-aminolevulinic acid) levels, deserve special attention.
|
| author |
Mejía, José Julián Jaramillo Trujillo, Gilberto Gómez, Luis Fernando Jaramillo, María Andrea Caballero Tovar, Dayana Milena |
| author_facet |
Mejía, José Julián Jaramillo Trujillo, Gilberto Gómez, Luis Fernando Jaramillo, María Andrea Caballero Tovar, Dayana Milena |
| topicspa_str_mv |
diagnóstico Porfiria aguda clasificación tratamiento |
| topic |
diagnóstico Porfiria aguda clasificación tratamiento treatment classification Acute porphyria diagnosis |
| topic_facet |
diagnóstico Porfiria aguda clasificación tratamiento treatment classification Acute porphyria diagnosis |
| citationvolume |
29 |
| citationissue |
1 |
| citationedition |
Núm. 1 , Año 2020 : Enero - Abril |
| publisher |
Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud |
| ispartofjournal |
Revista Repertorio de Medicina y Cirugía |
| source |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/886 |
| language |
Español |
| format |
Article |
| rights |
https://creativecommons.org/licenses/by-nc-sa/4.0/ Revista Repertorio de Medicina y Cirugía - 2020 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 |
| references |
Bonkovsky HL, Guo JT, Hou W, Li T, Narang T, Thapar M. Porphyrin and heme metabolism and the porphyrias. Compr Physiol. 2013;3(1):365-401. 2. Bissell DM, Wang B. Acute Hepatic Porphyria. J Clin Transl Hepatol. 2015;3(1):17-26. doi: 10.14218/JCTH.2014.00039 3. Bonkovsky HL, Cable EE, Cable JW, Donohue SE, White EC, Greene YJ, et al. Porphyrogenic properties of the terpenes camphor, pinene, and thujone (with a note on historic implications for absinthe and the illness of Vincent van Gogh). Biochem Pharmacol. 1992;43(11):2359-68. doi: 10.1016/0006-2952(92)90314-9. 4. Winkler MG, Anderson KE. Vampires, porphyria, and the media: medicalization of a myth. Perspect Biol Med. 1990;33(4):598-611. 5. Siegesmund M, van Tuyll van Serooskerken AM, Poblete-Gutierrez P, Frank J. The acute hepatic porphyrias: current status and future challenges. Best Pract Res Clin Gastroenterol. 2010;24(5):593-605. doi: 10.1016/j.bpg.2010.08.010 6. Besur S, Schmeltzer P, Bonkovsky HL. Acute Porphyrias. J Emerg Med. 2015;49(3):305-12. doi: 10.1016/j.jemermed.2015.04.034 7. Meissner PN, Dailey TA, Hift RJ, Ziman M, Corrigall AV, Roberts AG, et al. A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet. 1996;13(1):95-7. doi: 10.1038/ng0596-95 8. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924-37. 9. Fuller S, Wiley J. Heme Biosynthesis and Its Disorders: Porphyrias and Sideroblastic Anemias. In: John Anastasi LS, editor. Hematology: Basic Principles and Practice. Livingstone: Elsevier; 2013. p. 457-72.e5. 10. Chiabrando D, Mercurio S, Tolosano E. Heme and erythropoieis: more than a structural role. Haematologica. 2014;99(6):973-83. doi: 10.3324/haematol.2013.091991 11. Furuyama K, Sassa S. Interaction between succinyl CoA synthetase and the heme-biosynthetic enzyme ALAS-E is disrupted in sideroblastic anemia. J Clin Invest. 2000;105(6):757-64. doi: 10.1172/JCI6816 12. Shaw GC, Cope JJ, Li L, Corson K, Hersey C, Ackermann GE, et al. Mitoferrin is essential for erythroid iron assimilation. Nature. 2006;440(7080):96-100. doi: 10.1038/nature04512 13. Sassa S. Hematologic aspects of the porphyrias. Int J Hematol. 2000;71(1):1-17. 14. Besur S, Hou W, Schmeltzer P, Bonkovsky HL. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites. 2014;4(4):977-1006. doi: 10.3390/metabo4040977 15. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201-14. doi: 10.2147/TACG.S48605 16. Simon NG, Herkes GK. The neurologic manifestations of the acute porphyrias. J Clin Neurosci: official journal of the Neurosurgical Society of Australasia. 2011;18(9):1147-53. doi: 10.1016/j.jocn.2011.01.003 17. Hermes-Lima M, Castilho RF, Valle VG, Bechara EJ, Vercesi AE. Calcium-dependent mitochondrial oxidative damage promoted by 5-aminolevulinic acid. Biochim Biophys Acta. 1992;1180(2):201-6. doi: 10.1016/0925-4439(92)90069-y 18. Felitsyn N, McLeod C, Shroads AL, Stacpoole PW, Notterpek L. The heme precursor delta-aminolevulinate blocks peripheral myelin formation. J Neurochem. 2008;106(5):2068-79. doi: 10.1111/j.1471-4159.2008.05552.x. 19. Percy VA, Shanley BC. Studies on haem biosynthesis in rat brain. J Neurochem. 1979;33(6):1267-74. doi: 10.1111/j.1471-4159.1979.tb05273.x 20. Lin CS, Krishnan AV, Lee MJ, Zagami AS, You HL, Yang CC, et al. Nerve function and dysfunction in acute intermittent porphyria. Brain : a journal of neurology. 2008;131(Pt 9):2510-9. doi: 10.1093/brain/awn152. 21. Horn S, Quasthoff S, Grafe P, Bostock H, Renner R, Schrank B. Abnormal axonal inward rectification in diabetic neuropathy. Muscle Nerve. 1996;19(10):1268-75. doi: 10.1002/mus.880191002 22. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore). 1992;71(1):1-13. 23. Herrick AL, McColl KEL. Acute intermittent porphyria. Best practice & research Clinical gastroenterology. 2005;19(2):235-49. doi: 10.1016/j.bpg.2004.10.006 24. Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood. 2012;120(23):4496-504. doi: 10.1182/blood-2012-05-423186 25. Hasanoglu A, Balwani M, Kasapkara CS, Ezgu FS, Okur I, Tumer L, et al. Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R. J Inherit Metab Dis. 2011;34(1):225-31. doi: 10.1007/s10545-010-9237-9. 26. Ventura P, Cappellini MD, Biolcati G, Guida CC, Rocchi E. A challenging diagnosis for potential fatal diseases: recommendations for diagnosing acute porphyrias. Eur J Intern Med. 2014;25(6):497-505. doi: 10.1016/j.ejim.2014.03.011 27. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439-50. doi: 10.7326/0003-4819-142-6-200503150-00010 28. Elder GH, Hift RJ, Meissner PN. The acute porphyrias. Lancet. 1997;349(9065):1613-7. doi: 10.1016/S0140-6736(96)09070-8 29. Hift RJ, Peters TJ, Meissner PN. A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the 'Royal Malady'. J Clin Pathol. 2012;65(3):200-5. doi: 10.1136/jclinpath-2011-200276 30. Sassa S. ALAD porphyria. Semin Liver Dis. 1998;18(1):95-101. doi: 10.1055/s-2007-1007145 31. Herman DS, Geraldine M, Venkatesh T. Evaluation, diagnosis, and treatment of lead poisoning in a patient with occupational lead exposure: a case presentation. J Occup Med Toxicol. 2007;2:7. doi: 10.1186/1745-6673-2-7 32. Bonkovsky HL. Neurovisceral porphyrias: what a hematologist needs to know. Hematology American Society of Hematology Education Program. 2005:24-30. doi: 10.1182/asheducation-2005.1.24 33. Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-le-grand). 2009;55(1):72-83. 34. Crimlisk HL. The little imitator--porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry. 1997;62(4):319-28. doi: 10.1136/jnnp.62.4.319 35. Hindmarsh JT. The porphyrias, appropriate test selection. Clinica chimica acta; international journal of clinical chemistry. 2003;333(2):203-7. doi: 10.1016/s0009-8981(03)00187-6 36. Guilard R, Kadish K, Smith K. The Porphyrin Handbook: Elsevier; 2003. 37. Elder GH, Hift RJ. Treatment of acute porphyria. Hosp Med. 2001;62(7):422-5. 38. Disler PB, Eales L. The acute attack of porphyria. S Afr Med J = Suid-Afrikaanse tydskrif vir geneeskunde. 1982;61(3):82-4. 39. Karim Z, Lyoumi S, Nicolas G, Deybach JC, Gouya L, Puy H. Porphyrias: A 2015 update. Clin Res Hepatol Gastroenterol. 2015;39(4):412-25. doi: 10.1016/j.clinre.2015.05.009 40. Lai CK, Lam CW, Chan YW. High-performance thin-layer chromatography of free porphyrins for diagnosis of porphyria. Clin Chem. 1994;40(11 Pt 1):2026-9. 41. Sardh E, Andersson DE, Henrichson A, Harper P. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell Mol Biol (Noisy-le-grand). 2009;55(1):66-71. 42. With TK. Simple and rapid screening for acute porphyria--'porphobilistix' and Hoesch test. S Afr Med J. = Suid-Afrikaanse tydskrif vir geneeskunde. 1971:229-30. 43. Deacon AC, Peters TJ. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem. 1998;35 ( Pt 6):726-32. doi: 10.1177/000456329803500604 44. McEwen J, Paterson C. Drugs and false-positive screening tests for porphyria. Br Med J. 1972;1(5797):421. doi: 10.1136/bmj.1.5797.421 45. Frith D, Yeung K, Thrush S, Hunt BJ, Hubbard JG. Lead poisoning--a differential diagnosis for abdominal pain. Lancet. 2005;366(9503):2146. doi: 10.1016/S0140-6736(05)67893-2 46. Akagi R, Inoue R, Muranaka S, Tahara T, Taketani S, Anderson KE, et al. Dual gene defects involving delta-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient. British journal of haematology. 2006;132(2):237-43. doi: 10.1111/j.1365-2141.2005.05852.x 47. De Rooij F, Edixhoven A, P. Wilson JH. Porphyria: A Diagnostic Approach. In: Kadish KM, Smith KM, Guilard R, editors. The Porphyrin Handbook: Elsevier; 2003. p. 93. 48. Sardh E, Harper P, Andersson DE, Floderus Y. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks. Eur J Intern Med. 2009;20(2):201-7. doi: 10.1016/j.ejim.2008.06.012 49. Erlandsen EJ, Jorgensen PE, Markussen S, Brock A. Determination of porphobilinogen deaminase activity in human erythrocytes: pertinent factors in obtaining optimal conditions for measurements. Scand J Clin Lab Invest. 2000;60(7):627-34. 50. Di Pierro E, Brancaleoni V, Besana V, Cappellini MD. Multiplex ligation-dependent probe amplification: a novel approach for genetic diagnosis of Porphyria. J Hum Genet. 2009;54(8):479-87. doi: 10.1038/jhg.2009.67. 51. De Siervi A, Varela LS, Parera VE, Batlle AM, Rossetti MV. Diagnosis of latent acute intermittent porphyria by genetic analysis. Ann Clin Biochem. 2001;38(Pt 2):149-52. doi: 10.1258/0004563011900344 52. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med. 1993;153(17):2004-8. 53. Chemmanur AT, Bonkovsky HL. Hepatic porphyrias: diagnosis and management. Clin Liver Dis. 2004;8(4):807-38, viii. doi: 10.1016/j.cld.2004.07.001 54. Desnick RJ, Balwani M. The Porphyrias. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 19 ed: McGraw-Hill; 2015. 55. Marsden JT, Guppy S, Stein P, Cox TM, Badminton M, Gardiner T, et al. Audit of the Use of Regular Haem Arginate Infusions in Patients with Acute Porphyria to Prevent Recurrent Symptoms. JIMD Rep. 2015;22:57-65. doi: 10.1007/8904_2015_411 56. Stein P, Badminton M, Barth J, Rees D, Stewart MF. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem. 2013;50(Pt 3):217-23. doi: 10.1177/0004563212474555 57. Jones SR, Bell A, Brink G. Treatment of acute intermittent porphyria in the emergency department. J Emerg Nurs: JEN : official publication of the Emergency Department Nurses Association. 2014;40(3):257-9; quiz 92-3. doi: 10.1016/j.jen.2013.11.014 58. López O, Lemus E. Porfiria intermitente aguda: presentación de un caso y revisión de la literatura. Acta Colombiana de Cuidado Intensivo 2008;8(2):110-5. 59. González W, Hernán Rodríguez J. Manejo médico y farmacológico del estatus epiléptico. Acta Neurológica Colombiana. 2011;27:39-46. 60. Mehta M, Rath GP, Padhy UP, Marda M, Mahajan C, Dash HH. Intensive care management of patients with acute intermittent porphyria: Clinical report of four cases and review of literature. Indian journal of critical care medicine : peer-reviewed, official publication of Indian J Crit Care Med. 2010;14(2):88-91. doi: 10.4103/0972-5229.68222 61. Harrison JC, McAuley FT. Propofol for sedation in intensive care in a patient with an acute porphyric attack. Anaesthesia. 1992;47(4):355-6. doi: 10.1111/j.1365-2044.1992.tb02186.x 62. Pandey CK, Singh N, Bose N, Sahay S. Gabapentin and propofol for treatment of status epilepticus in acute intermittent porphyria. J Postgrad Med. 2003;49(3):285. 63. Yandel ML, Watters MR. Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resected anaplastic glioma. Clin Neurol Neurosurg. 1995;97(3):261-3. 64. Zaatreh MM. Levetiracetam in porphyric status epilepticus: a case report. Clin Neuropharmacol. 2005;28(5):243-4. 65. Robert TL, Varella L, Meguid MM. Nutrition management of acute intermittent porphyria. Nutrition. 1994;10(6):551-5; quiz 6-7. 66. Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol. 1991;86(8):1050-6. 67. Anderson KE, Bonkovsky HL, Bloomer JR, Shedlofsky SI. Reconstitution of hematin for intravenous infusion. Ann of Intern Med. 2006;144(7):537-8. doi: 10.7326/0003-4819-144-7-200604040-00023 68. Mendenhall DW. Instability of hematin solutions. N Engl J Med. 1984;311(8):539. doi: 10.1056/NEJM198408233110819 69. Goetsch CA, Bissell DM. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med. 1986;315(4):235-8. doi: 10.1056/NEJM198607243150406 70. Badminton MN, Deybach JC. Treatment of an acute attack of porphyria during pregnancy. Eur J Neurol. 2006;13(6):668-9. doi: 10.1111/j.1468-1331.2006.01238.x 71. Pischik E, Kauppinen R. Can pregnancy stop cyclical attacks of porphyria?. Am J Med. 2006;119(1):88-90. 72. Tenhunen R, Mustajoki P. Acute porphyria: treatment with heme. Seminars in liver disease. 1998;18(1):53-5. doi: 10.1016/j.amjmed.2005.08.032 73. Sardh E, Rejkjaer L, Andersson DE, Harper P. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet. 2007;46(4):335-49. doi: 10.2165/00003088-200746040-00006 74. Jeans JB, Savik K, Gross CR, Weimer MK, Bossenmaier IC, Pierach CA, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet. 1996;65(4):269-73. doi: 10.1002/(SICI)1096-8628(19961111)65:4<269::AID-AJMG4>3.0.CO;2-K 75. Andant C, Puy H, Bogard C, Faivre J, Soule JC, Nordmann Y, et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol. 2000;32(6):933-9. |
| type_driver |
info:eu-repo/semantics/article |
| type_coar |
http://purl.org/coar/resource_type/c_6501 |
| type_version |
info:eu-repo/semantics/publishedVersion |
| type_coarversion |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| type_content |
Text |
| publishDate |
2020-03-16 |
| date_accessioned |
2020-03-16T00:00:00Z |
| date_available |
2020-03-16T00:00:00Z |
| url |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/886 |
| url_doi |
https://doi.org/10.31260/RepertMedCir.v29.n1.2020.886 |
| issn |
0121-7372 |
| eissn |
2462-991X |
| doi |
10.31260/RepertMedCir.v29.n1.2020.886 |
| url4_str_mv |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/886/1169 |
| url7_str_mv |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/886/1208 |
| url5_str_mv |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/886/1135 |
| url3_str_mv |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/886/1134 |
| url2_str_mv |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/886/1257 |
| _version_ |
1797159836125757440 |
| spelling |
Porfirias agudas: manifestaciones inespecíficas y manejo terapéutico específico Bonkovsky HL, Guo JT, Hou W, Li T, Narang T, Thapar M. Porphyrin and heme metabolism and the porphyrias. Compr Physiol. 2013;3(1):365-401. 2. Bissell DM, Wang B. Acute Hepatic Porphyria. J Clin Transl Hepatol. 2015;3(1):17-26. doi: 10.14218/JCTH.2014.00039 3. Bonkovsky HL, Cable EE, Cable JW, Donohue SE, White EC, Greene YJ, et al. Porphyrogenic properties of the terpenes camphor, pinene, and thujone (with a note on historic implications for absinthe and the illness of Vincent van Gogh). Biochem Pharmacol. 1992;43(11):2359-68. doi: 10.1016/0006-2952(92)90314-9. 4. Winkler MG, Anderson KE. Vampires, porphyria, and the media: medicalization of a myth. Perspect Biol Med. 1990;33(4):598-611. 5. Siegesmund M, van Tuyll van Serooskerken AM, Poblete-Gutierrez P, Frank J. The acute hepatic porphyrias: current status and future challenges. Best Pract Res Clin Gastroenterol. 2010;24(5):593-605. doi: 10.1016/j.bpg.2010.08.010 6. Besur S, Schmeltzer P, Bonkovsky HL. Acute Porphyrias. J Emerg Med. 2015;49(3):305-12. doi: 10.1016/j.jemermed.2015.04.034 7. Meissner PN, Dailey TA, Hift RJ, Ziman M, Corrigall AV, Roberts AG, et al. A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet. 1996;13(1):95-7. doi: 10.1038/ng0596-95 8. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924-37. 9. Fuller S, Wiley J. Heme Biosynthesis and Its Disorders: Porphyrias and Sideroblastic Anemias. In: John Anastasi LS, editor. Hematology: Basic Principles and Practice. Livingstone: Elsevier; 2013. p. 457-72.e5. 10. Chiabrando D, Mercurio S, Tolosano E. Heme and erythropoieis: more than a structural role. Haematologica. 2014;99(6):973-83. doi: 10.3324/haematol.2013.091991 11. Furuyama K, Sassa S. Interaction between succinyl CoA synthetase and the heme-biosynthetic enzyme ALAS-E is disrupted in sideroblastic anemia. J Clin Invest. 2000;105(6):757-64. doi: 10.1172/JCI6816 12. Shaw GC, Cope JJ, Li L, Corson K, Hersey C, Ackermann GE, et al. Mitoferrin is essential for erythroid iron assimilation. Nature. 2006;440(7080):96-100. doi: 10.1038/nature04512 13. Sassa S. Hematologic aspects of the porphyrias. Int J Hematol. 2000;71(1):1-17. 14. Besur S, Hou W, Schmeltzer P, Bonkovsky HL. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites. 2014;4(4):977-1006. doi: 10.3390/metabo4040977 15. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201-14. doi: 10.2147/TACG.S48605 16. Simon NG, Herkes GK. The neurologic manifestations of the acute porphyrias. J Clin Neurosci: official journal of the Neurosurgical Society of Australasia. 2011;18(9):1147-53. doi: 10.1016/j.jocn.2011.01.003 17. Hermes-Lima M, Castilho RF, Valle VG, Bechara EJ, Vercesi AE. Calcium-dependent mitochondrial oxidative damage promoted by 5-aminolevulinic acid. Biochim Biophys Acta. 1992;1180(2):201-6. doi: 10.1016/0925-4439(92)90069-y 18. Felitsyn N, McLeod C, Shroads AL, Stacpoole PW, Notterpek L. The heme precursor delta-aminolevulinate blocks peripheral myelin formation. J Neurochem. 2008;106(5):2068-79. doi: 10.1111/j.1471-4159.2008.05552.x. 19. Percy VA, Shanley BC. Studies on haem biosynthesis in rat brain. J Neurochem. 1979;33(6):1267-74. doi: 10.1111/j.1471-4159.1979.tb05273.x 20. Lin CS, Krishnan AV, Lee MJ, Zagami AS, You HL, Yang CC, et al. Nerve function and dysfunction in acute intermittent porphyria. Brain : a journal of neurology. 2008;131(Pt 9):2510-9. doi: 10.1093/brain/awn152. 21. Horn S, Quasthoff S, Grafe P, Bostock H, Renner R, Schrank B. Abnormal axonal inward rectification in diabetic neuropathy. Muscle Nerve. 1996;19(10):1268-75. doi: 10.1002/mus.880191002 22. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore). 1992;71(1):1-13. 23. Herrick AL, McColl KEL. Acute intermittent porphyria. Best practice & research Clinical gastroenterology. 2005;19(2):235-49. doi: 10.1016/j.bpg.2004.10.006 24. Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood. 2012;120(23):4496-504. doi: 10.1182/blood-2012-05-423186 25. Hasanoglu A, Balwani M, Kasapkara CS, Ezgu FS, Okur I, Tumer L, et al. Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R. J Inherit Metab Dis. 2011;34(1):225-31. doi: 10.1007/s10545-010-9237-9. 26. Ventura P, Cappellini MD, Biolcati G, Guida CC, Rocchi E. A challenging diagnosis for potential fatal diseases: recommendations for diagnosing acute porphyrias. Eur J Intern Med. 2014;25(6):497-505. doi: 10.1016/j.ejim.2014.03.011 27. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439-50. doi: 10.7326/0003-4819-142-6-200503150-00010 28. Elder GH, Hift RJ, Meissner PN. The acute porphyrias. Lancet. 1997;349(9065):1613-7. doi: 10.1016/S0140-6736(96)09070-8 29. Hift RJ, Peters TJ, Meissner PN. A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the 'Royal Malady'. J Clin Pathol. 2012;65(3):200-5. doi: 10.1136/jclinpath-2011-200276 30. Sassa S. ALAD porphyria. Semin Liver Dis. 1998;18(1):95-101. doi: 10.1055/s-2007-1007145 31. Herman DS, Geraldine M, Venkatesh T. Evaluation, diagnosis, and treatment of lead poisoning in a patient with occupational lead exposure: a case presentation. J Occup Med Toxicol. 2007;2:7. doi: 10.1186/1745-6673-2-7 32. Bonkovsky HL. Neurovisceral porphyrias: what a hematologist needs to know. Hematology American Society of Hematology Education Program. 2005:24-30. doi: 10.1182/asheducation-2005.1.24 33. Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-le-grand). 2009;55(1):72-83. 34. Crimlisk HL. The little imitator--porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry. 1997;62(4):319-28. doi: 10.1136/jnnp.62.4.319 35. Hindmarsh JT. The porphyrias, appropriate test selection. Clinica chimica acta; international journal of clinical chemistry. 2003;333(2):203-7. doi: 10.1016/s0009-8981(03)00187-6 36. Guilard R, Kadish K, Smith K. The Porphyrin Handbook: Elsevier; 2003. 37. Elder GH, Hift RJ. Treatment of acute porphyria. Hosp Med. 2001;62(7):422-5. 38. Disler PB, Eales L. The acute attack of porphyria. S Afr Med J = Suid-Afrikaanse tydskrif vir geneeskunde. 1982;61(3):82-4. 39. Karim Z, Lyoumi S, Nicolas G, Deybach JC, Gouya L, Puy H. Porphyrias: A 2015 update. Clin Res Hepatol Gastroenterol. 2015;39(4):412-25. doi: 10.1016/j.clinre.2015.05.009 40. Lai CK, Lam CW, Chan YW. High-performance thin-layer chromatography of free porphyrins for diagnosis of porphyria. Clin Chem. 1994;40(11 Pt 1):2026-9. 41. Sardh E, Andersson DE, Henrichson A, Harper P. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell Mol Biol (Noisy-le-grand). 2009;55(1):66-71. 42. With TK. Simple and rapid screening for acute porphyria--'porphobilistix' and Hoesch test. S Afr Med J. = Suid-Afrikaanse tydskrif vir geneeskunde. 1971:229-30. 43. Deacon AC, Peters TJ. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem. 1998;35 ( Pt 6):726-32. doi: 10.1177/000456329803500604 44. McEwen J, Paterson C. Drugs and false-positive screening tests for porphyria. Br Med J. 1972;1(5797):421. doi: 10.1136/bmj.1.5797.421 45. Frith D, Yeung K, Thrush S, Hunt BJ, Hubbard JG. Lead poisoning--a differential diagnosis for abdominal pain. Lancet. 2005;366(9503):2146. doi: 10.1016/S0140-6736(05)67893-2 46. Akagi R, Inoue R, Muranaka S, Tahara T, Taketani S, Anderson KE, et al. Dual gene defects involving delta-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient. British journal of haematology. 2006;132(2):237-43. doi: 10.1111/j.1365-2141.2005.05852.x 47. De Rooij F, Edixhoven A, P. Wilson JH. Porphyria: A Diagnostic Approach. In: Kadish KM, Smith KM, Guilard R, editors. The Porphyrin Handbook: Elsevier; 2003. p. 93. 48. Sardh E, Harper P, Andersson DE, Floderus Y. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks. Eur J Intern Med. 2009;20(2):201-7. doi: 10.1016/j.ejim.2008.06.012 49. Erlandsen EJ, Jorgensen PE, Markussen S, Brock A. Determination of porphobilinogen deaminase activity in human erythrocytes: pertinent factors in obtaining optimal conditions for measurements. Scand J Clin Lab Invest. 2000;60(7):627-34. 50. Di Pierro E, Brancaleoni V, Besana V, Cappellini MD. Multiplex ligation-dependent probe amplification: a novel approach for genetic diagnosis of Porphyria. J Hum Genet. 2009;54(8):479-87. doi: 10.1038/jhg.2009.67. 51. De Siervi A, Varela LS, Parera VE, Batlle AM, Rossetti MV. Diagnosis of latent acute intermittent porphyria by genetic analysis. Ann Clin Biochem. 2001;38(Pt 2):149-52. doi: 10.1258/0004563011900344 52. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med. 1993;153(17):2004-8. 53. Chemmanur AT, Bonkovsky HL. Hepatic porphyrias: diagnosis and management. Clin Liver Dis. 2004;8(4):807-38, viii. doi: 10.1016/j.cld.2004.07.001 54. Desnick RJ, Balwani M. The Porphyrias. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 19 ed: McGraw-Hill; 2015. 55. Marsden JT, Guppy S, Stein P, Cox TM, Badminton M, Gardiner T, et al. Audit of the Use of Regular Haem Arginate Infusions in Patients with Acute Porphyria to Prevent Recurrent Symptoms. JIMD Rep. 2015;22:57-65. doi: 10.1007/8904_2015_411 56. Stein P, Badminton M, Barth J, Rees D, Stewart MF. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem. 2013;50(Pt 3):217-23. doi: 10.1177/0004563212474555 57. Jones SR, Bell A, Brink G. Treatment of acute intermittent porphyria in the emergency department. J Emerg Nurs: JEN : official publication of the Emergency Department Nurses Association. 2014;40(3):257-9; quiz 92-3. doi: 10.1016/j.jen.2013.11.014 58. López O, Lemus E. Porfiria intermitente aguda: presentación de un caso y revisión de la literatura. Acta Colombiana de Cuidado Intensivo 2008;8(2):110-5. 59. González W, Hernán Rodríguez J. Manejo médico y farmacológico del estatus epiléptico. Acta Neurológica Colombiana. 2011;27:39-46. 60. Mehta M, Rath GP, Padhy UP, Marda M, Mahajan C, Dash HH. Intensive care management of patients with acute intermittent porphyria: Clinical report of four cases and review of literature. Indian journal of critical care medicine : peer-reviewed, official publication of Indian J Crit Care Med. 2010;14(2):88-91. doi: 10.4103/0972-5229.68222 61. Harrison JC, McAuley FT. Propofol for sedation in intensive care in a patient with an acute porphyric attack. Anaesthesia. 1992;47(4):355-6. doi: 10.1111/j.1365-2044.1992.tb02186.x 62. Pandey CK, Singh N, Bose N, Sahay S. Gabapentin and propofol for treatment of status epilepticus in acute intermittent porphyria. J Postgrad Med. 2003;49(3):285. 63. Yandel ML, Watters MR. Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resected anaplastic glioma. Clin Neurol Neurosurg. 1995;97(3):261-3. 64. Zaatreh MM. Levetiracetam in porphyric status epilepticus: a case report. Clin Neuropharmacol. 2005;28(5):243-4. 65. Robert TL, Varella L, Meguid MM. Nutrition management of acute intermittent porphyria. Nutrition. 1994;10(6):551-5; quiz 6-7. 66. Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol. 1991;86(8):1050-6. 67. Anderson KE, Bonkovsky HL, Bloomer JR, Shedlofsky SI. Reconstitution of hematin for intravenous infusion. Ann of Intern Med. 2006;144(7):537-8. doi: 10.7326/0003-4819-144-7-200604040-00023 68. Mendenhall DW. Instability of hematin solutions. N Engl J Med. 1984;311(8):539. doi: 10.1056/NEJM198408233110819 69. Goetsch CA, Bissell DM. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med. 1986;315(4):235-8. doi: 10.1056/NEJM198607243150406 70. Badminton MN, Deybach JC. Treatment of an acute attack of porphyria during pregnancy. Eur J Neurol. 2006;13(6):668-9. doi: 10.1111/j.1468-1331.2006.01238.x 71. Pischik E, Kauppinen R. Can pregnancy stop cyclical attacks of porphyria?. Am J Med. 2006;119(1):88-90. 72. Tenhunen R, Mustajoki P. Acute porphyria: treatment with heme. Seminars in liver disease. 1998;18(1):53-5. doi: 10.1016/j.amjmed.2005.08.032 73. Sardh E, Rejkjaer L, Andersson DE, Harper P. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet. 2007;46(4):335-49. doi: 10.2165/00003088-200746040-00006 74. Jeans JB, Savik K, Gross CR, Weimer MK, Bossenmaier IC, Pierach CA, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet. 1996;65(4):269-73. doi: 10.1002/(SICI)1096-8628(19961111)65:4<269::AID-AJMG4>3.0.CO;2-K 75. Andant C, Puy H, Bogard C, Faivre J, Soule JC, Nordmann Y, et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol. 2000;32(6):933-9. application/epub+zip audio/mpeg Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud Revista Repertorio de Medicina y Cirugía https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/886 Español https://creativecommons.org/licenses/by-nc-sa/4.0/ Revista Repertorio de Medicina y Cirugía - 2020 info:eu-repo/semantics/article application/pdf http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_dcae04bc http://purl.org/redcol/resource_type/ARTREV info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Text text/html text/xml Publication diagnóstico Revisión clínica, científica, teórica y documental teniendo como objetivo principal realizar una revisión sobre la porfiria aguda, su enfoque, diagnóstico y tratamiento. Se utilizó una metodología descriptiva, cualitativa y teórica que permitió la revisión bibliográfica de los estudios relacionados con la porfiria aguda, trastorno congénito poco frecuente que causa alteraciones en las enzimas de la biosíntesis del grupo hem. La importancia de esta patología radica en que se confunde con otras enfermedades debido al cuadro clínico complejo difícil de identificar, lo que ocasiona un diagnóstico tardío que puede comprometer la vida del paciente y por ello se conoce como enfermedad silenciosa. Como conclusión se recomienda mayor atención a los factores precipitantes de los ataques agudos por la elevada morbimortalidad, así como hacer un diagnóstico rápido y oportuno por medios cualitativos y cuantitativos solicitando PBG (porfobilinógeno) y ALA (ácido delta aminolevulínico). Mejía, José Julián Jaramillo Trujillo, Gilberto Gómez, Luis Fernando Jaramillo, María Andrea Caballero Tovar, Dayana Milena Porfiria aguda clasificación tratamiento Núm. 1 , Año 2020 : Enero - Abril Artículo de revista 1 29 treatment This was a clinical, scientific, theoretical and documental review aimed to conduct a revision on the approach, diagnosis and treatment of acute porphyria. A descriptive, quantitative and theoretical methodology was used, allowing a bibliographic review of the studies on acute porphyria, an unusual congenital disorder characterized by the deficiency of specific enzymes involved in the heme group biosynthesis. This disease importance lies on being confused with other conditions due to its complex clinical manifestations leading to a delayed diagnosis which may become life-threatening thus it is known as a silent disease In conclusion, identifying the precipitating factors of acute attacks for its high morbidity and mortality, as well as achieving a rapid and timely diagnosis by using a quantitative or qualitative determination of PBG (porphobilinogen)) and ALA (delta-aminolevulinic acid) levels, deserve special attention. classification Acute porphyria Journal article Acute porphyrias: unspecific manifestations and specific therapeutic management diagnosis 2462-991X 2020-03-16 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/886/1169 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/886/1208 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/886/1135 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/886/1134 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/886/1257 0121-7372 2020-03-16T00:00:00Z https://doi.org/10.31260/RepertMedCir.v29.n1.2020.886 10.31260/RepertMedCir.v29.n1.2020.886 2020-03-16T00:00:00Z |